TKI 258 in Von Hippel-Lindau Syndrome (VHL)

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Von Hippel-Lindau Syndrome

Interventions

DRUG

Dovitinib

500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston